Jeff Evanson - Jan 17, 2023 Form 4 Insider Report for Outlook Therapeutics, Inc. (OTLK)

Role
Chief Commercial Officer
Signature
/s/ Lawrence Kenyon, Attorney-in-Fact
Stock symbol
OTLK
Transactions as of
Jan 17, 2023
Transactions value $
-$203,726
Form type
4
Date filed
1/19/2023, 07:05 PM
Previous filing
Apr 4, 2022
Next filing
Jan 24, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OTLK Common Stock Sale -$35.6K -27.2K -2.31% $1.31 1.15M Jan 17, 2023 Direct F1, F2
transaction OTLK Common Stock Sale -$42.2K -33.7K -2.93% $1.25 1.12M Jan 18, 2023 Direct F1, F2
transaction OTLK Common Stock Sale -$126K -103K -9.25% $1.22 1.01M Jan 19, 2023 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were sold to cover taxes upon lapse of Issuer's repurchase right as to 75% of the shares as provided in that certain Consulting Agreement dated January 27, 2020.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from within a $1.00 range. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.1909 - $1.265, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.